Abstract
Cough is a widespread symptom in children and adolescents. Despite advances in scientific knowledge about the neurophysiological mechanisms underlying the cough reflex, the best therapeutic approaches for children and adolescents who cough remain unclear, and many needs are still unmet. Many remedies for cough are self-prescribed, reflecting strong demand, but significant evidence of their efficacy and safety is missing in pediatric populations. Moreover, as most coughs are part of self-limited illnesses, treatment could be considered unnecessary in some patients. Drug therapy to relieve cough and other symptoms is an essential part of treating a child with cough. However, unfortunately, the number of studies in each category of cough medications is minimal, and dosing and treatment duration varies significantly among studies. Some treatments have been shown to be no more effective than placebo. Lack of clear indications for dosing and treatment duration, the number of available drugs, the numerous active ingredients in products, and multiple caregivers administering medication to children have been considered contributors to an increased risk of inappropriate prescribing, accidental overdosing, and adverse events. This review presents the most recent evidence on the safety and efficacy of available cough remedies, focusing on the pediatric age group, and includes H1 receptor antagonists, mucolytics and expectorants, drugs acting peripherally on the cough reflex, drugs acting centrally on the cough reflex, drugs acting both peripherally and centrally on the cough reflex, and other compounds, including menthol, glycerol, honey, and medical devices composed of complex natural substances. Future perspectives on new therapeutic targets are also discussed.
Similar content being viewed by others
References
US Food and Drug Administration. FDA releases recommendations regarding use of the over-the-counter cough and cold products. 2008. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116839.htm. Accessed 22 July 2020.
US Food and Drug Administration. OTC Cough and Cold Products: Not For Infants and Children Under 2 Years of Age; 2018. https://www.fda.gov/consumers/consumer-updates/otc-cough-and-cold-products-not-infants-and-children-under-2-years-age. Aaccessed 16 July 2020.
Parisi GF, Leonardi S, Ciprandi G, Corsico A, Licari A, Miraglia Del Giudice M, et al. cetirizine uses in childhood: an update of a friendly 30-year drug. Clin Mol Allergy. 2020;18:2.
Parisi GF, Licari A, Papale M, Manti S, Salpietro C, Marseglia GL, et al. Antihistamines: ABC for the pediatricians. Pediatr Allergy Immunol. 2020;31(Suppl 24):34–6.
Simons FER. Advances in H1-antihistamines. N Engl J Med. 2004;351:2203–17.
Chang AB, Peake J, McElrea MS. Anti-histamines for prolonged non-specific cough in children. Cochrane Database Syst Rev. 2008;2:CD005604.
Ciprandi G, Tosca M, Ricca V, Passalacqua G, Fregonese L, Fasce L, et al. Cetirizine treatment of allergic cough in children with pollen allergy. Allergy. 1997;52:752–4.
Ciprandi G, Tosca M, Ricca V, Passalacqua G, Riccio AM, Bagnasco M, et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy. 1997;27(10):1160–6.
Ciprandi G, Buscaglia S, Catrullo A, Marchesi E, Bianchi B, Canonica GW. Loratadine in the treatment of cough associated with allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol. 1995;75:115–20.
Wei H, Li W, Jiang Z, Xi X, Qi G. Clinical efficacy of montelukast sodium combined with budesonide or combined with loratadine in treating children with cough variant asthma and influence on inflammatory factors in the serum. Exp Ther Med. 2019;18(1):411–7.
Paul IM, Yoder KE, Crowell KR, Shaffer ML, McMillan HS, Carlson LC, et al. Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. Pediatrics. 2004;114:e85–e90.
Yoder KE, Shaffer ML, La Tournous SJ, Paul IM. Child assessment of dextromethorphan, diphenhydramine, and placebo for nocturnal cough due to upper respiratory infection. Clin Pediatr (Phila). 2006;45:633–40.
Shadkam MN, Mozaffari-Khosravi H, Mozayan MR. A comparison of the effect of honey, dextromethorphan, and diphenhydramine on nightly cough and sleep quality in children and their parents. J Altern Complement Med. 2010;16:787–93.
Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in community settings. Cochrane Database Syst Rev. 2014;2014(11):CD001831.
Clemens CJ, Taylor JA, Almquist JR, Quinn HC, Mehta A, Naylor GS. Is an antihistamine-decongestant combination effective in temporarily relieving symptoms of the common cold in preschool children? J Pediatr. 1997;130:463–6.
Hutton N, Wilson MH, Mellits ED, et al. Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. J Pediatr. 1991;118:125–30.
Unuvar E, Yildiz I, Kilic A, Toprak S, Selvi Aslan S, Aydin S, et al. Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomized, controlled trial. Int J Pediatr Otorhinolaryngol. 2007;71(8):1277–85.
Irwin RS, Baumann MH, Bolser DC, Boulet LP, Braman SS, Brightling CE, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:1S–23S.
Morice A, Kardos P. Comprehensive evidence-based review on European antitussives. BMJ Open Resp Res. 2016;3:e000137.
Palmer RB, Reynolds KM, Banner W, Bond GR, Kauffman RE, Paul IM, et al. Adverse events associated with diphenhydramine in children, 2008–2015. Clin Toxicol (Phila). 2020;58(2):99–106.
Olasińska-Wiśniewska A, Olasiński J, Grajek S. Cardiovascular safety of antihistamines. Postepy Dermatol Alergol. 2014;31(3):182–6.
https://webarchive.nationalarchives.gov.uk/20141206123425/http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con041374.pdf. Accessed 20 July 2020.
Australian Government. Department of Health and aging therapeutic goods administration. Review of cough and cold medicines in children. 2009. https://www.tga.gov.au/sites/default/files/consult-labelling-cough-cold-091022-review.pdf. Accessed 11 May 2020.
Sidhu G, Akhondi H. Loratadine. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2020.
Curran MP, Scott LJ, Perry CM. Cetirizine: a review of its use in allergic disorders. Drugs. 2004;64(5):523–61.
Dicpinigaitis PV, Morice AH, Birring SS, McGarvey L, Smith JA, Canning BJ, et al. Antitussive drugs–past, present, and future. Pharmacol Rev. 2014;66:468–512.
Hosoe H, Kaise T, Ohmori K, Isohama Y, Kai H, Takahama K, et al. Mucolytic and antitussive effects of erdosteine. J Pharm Pharmacol. 1999;51:959–66.
Dal Negro RW, Visconti M, Micheletto C, Tognella S. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulm Pharmacol Ther. 2008;21:304–8.
Dal Negro RW, Visconti M, Trevisan F, et al. Erdosteine 600 mg, but not placebo and NAC 1200mg, restore airway response to inhaled salbutamol 200 mcg in COPD. In: Poster presented at the ERS Annual Meeting, Stockholm, 15–19 September 2007.
Bolser DC. Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):238S–49S.
Shimura S, Okubo T, Maeda S, Aoki T, Tomioka M, Shindo Y, et al. Effect of expectorants on relaxation behavior of sputum viscoelasticity in vivo. Biorheology. 1983;20:677–83.
European Medicines Agency. Science Medicines. Health. Ambroxol and bromhexine containing medicinal products. September 10, 2015, EMA/PRAC/800767/201. https://www.ema.europa.eu/en/documents/referral/ambroxol-bromhexine-article-31-referral-prac-assessment-report_en.pdf. Accessed 15 May 2020.
Balli F, Bergamini B, Calistru P, Ciofu EP, Domenici R, Doros G, et al. Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children. Int J Clin Pharmacol Ther. 2007;45:16–22.
Thomson ML, Pavia D, Jones CJ, McQuiston TA. No demonstrable effect of S-carboxymethyl cysteine on the clearance of secretions from the human lung. Thorax. 1975;30:669–73.
Edwards GF, Steel AE, Scott JK, Jordan JW. S-carboxymethyl cysteine in the fluidification of sputum and treatment of chronic airway obstruction. Chest. 1976;70:506–13.
Bolser DC, Poliacek I, Jakus J, Fuller DD, Davenport PW. Neurogenesis of cough, other airway defensive behaviors, and breathing: a hierarchical system? Respir Physiol Neurobiol. 2006;152:255–65.
Lavezzo A, Melillo G, Clavenna G, Omini C. Peripheral site of action of levodropropizine in experimental-induced cough: role of sensory neuropeptides. Pulm Pharmacol. 1992;5:143–7.
Mannini C, Lavorini F, Zanasi A, Saibene F, Lanata L, Fontana G. A randomized clinical trial comparing the effects of antitussive agents on respiratory center output in patients with chronic cough. Chest. 2017;151(6):1288–94.
Zanasi A, Lanata L, Fontana G, Saibene F, Dicpinigaitis P, De Blasio F. Levodropropizine for treating cough in adults and children: a meta-analysis of published studies. Multidiscip Respir Med. 2015;10:19.
Fiocchi R, Arancio P, Murgo G, Banderali G. Levodropropizine effectiveness on nocturnal cough in asthmatic children. Eur Respir J. 1991;4:594.
Banderali G, Riva E, Fiocchi A, Cordaro CI, Giovannini M. Efficacy and tolerability of levodropropizine and dropropizine in children with non-productive cough. J Int Med Res. 1995;23:175–83.
Kim DS, Sohn MH, Jang GC. Levodropropizine in children with bronchitis. Diagn Treat. 2002;22:9.
De Blasio F, Dicpinigaitis PV, Rubin BK, De Danieli G, Lanata L, Zanasi A. An observational study on cough in children: epidemiology, impact on the quality of sleep and treatment outcome. Cough. 2012;8:1.
Zanasi A, Lanata L, Saibene F, Fontana G, Dicpinigaitis PV, Venier V, et al. Prospective study of the efficacy of antibiotics versus antitussive drugs for the management of URTI-related acute cough in children. Multidiscip Respir Med. 2016;11:29.
Choudry NB, Fuller RW, Anderson N, Karlsson JA. Separation of cough and reflex bronchoconstriction by inhaled local anesthetics. Eur Respir J. 1990;3(5):579–83.
Belvisi MG, Geppetti P. Cough: current and future drugs for the treatment of chronic cough. Thorax. 2004;59:438–40.
Truesdale K, Jurdi A. Nebulized lidocaine in the treatment of intractable cough. Am J Hosp Palliat Care. 2013;30(6):587–9.
Tan W, Li S, Liu X, Gao X, Huang W, Guo J, Wang Z. Prophylactic intravenous lidocaine at different doses for fentanyl-induced cough (FIC): a meta-analysis. Sci Rep. 2018;8:9946.
Doona M, Walsh D. Benzonatate for opioid-resistant cough in advanced cancer. Palliat Med. 1998;12(1):55–8.
Korppi M, Laurikainen K, Pietikäinen M, Silvasti M. Antitussives in the treatment of acute transient cough in children. Acta Paediatr Scand. 1991;80:969–71.
Paul IM, Beiler J, McMonagle A, Shaffer ML, Duda L, Berlin CM Jr. Effect of honey, dextromethorphan, and no treatment on nocturnal cough and sleep quality for coughing children and their parents. Arch Pediatr Adolesc Med. 2007;161(12):1140–6.
Chang AB, Glomb WB. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 suppl):260S–83S.
Journey JD, Agrawal S, Stern E. Dextromethorphan Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. https://www.ncbi.nlm.nih.gov/books/NBK538502/. Accessed 6 July 2019.
Chyka PA, Erdman AR, Manoguerra AS, Christianson G, Booze LL, Nelson LS, et al. Dextromethorphan poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(6):662–77.
Taylor JA, Novack AH, Almquist JR, Rogers JE. Efficacy of cough suppressants in children. J Paediatr. 1993;122:799–802.
US Food and Drug Administration. Codeine cough-and-cold medicines in children: drug safety communication - FDA evaluating the potential risk of serious side effects, July 7, 2015. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm453379. Accessed 28 Apr 2020.
Codeine containing medicinal products for the treatment of cough and/or cold in pediatric patients. Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data. March 12 2015EMA/235820/2015. https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-prac-assessment-report_en-0.
Scotti L, Borzani M. Cloperastine fendizoate in the treatment of cough-producing diseases in pediatrics. Minerva Pediatr. 1988;40:283–6.
Cicchetti M. Cloperastine syrup (Seki) in the treatment of cough in children. Aggiornamento Pediatrico. 1983;34:325–50.
Svitaylo OA. Efficacy and tolerability of cloperastine fendizoate in the treatment of children and adolescents with a cough caused by respiratory infections: effect on night-time cough and the quality of sleep of patients and parents. A randomized, double-blind, placebo-controlled study. Int J Drugs Ther. 2005;22:35–433.
Aliprandi P, Castelli C, Bernorio S, Dell'Abate E, Carrara M. Levocloperastine in the treatment of chronic non-productive cough: comparative efficacy versus standard antitussive agents. Drugs Exp Clin Res. 2004;30:133–41.
Abelmann WH, Gaensler EA, Badger TL. Clinical evaluation of toryn, a new synthetic cough depressant. Dis Chest. 1954;25:532–41.
Glick J. Codeine vs. caramiphen in cough control. Del Med J. 1963;35:180.
Bickerman HA, Itkin SE. Further studies on the evaluation of antitussive agents employing experimentally induced cough in human subjects. Clin Pharmacol Ther. 1960;1:180–91.
Oral prescription drugs offered for relief of symptoms of cough, cold, or allergy; drug efficacy study implementation; caramiphen edisylate; final actions on supplemental new drug applications. Federal Register. 2000;65:42017
Kobayashi T, Ikeda K, Ichikawa T, Togashi S, Kumanishi T. Effects of sigma ligands on the cloned mu-, delta- and kappa-opioid receptors co-expressed with G-protein-activated K+ (GIRK) channel in Xenopus oocytes. Br J Pharmacol. 1996;119:73–80.
https://www.federalregister.gov/documents/2014/07/02/2014-15371/additions-and-modifications-to-the-list-of-drug-products-that-have-been-withdrawn-or-removed-from. Accessed 20 July 2020.
Kamatou GP, Vermaak I, Viljoen AM, Lawrence BM. Menthol: a simple monoterpene with remarkable biological properties. Phytochemistry. 2013;96:15–25.
Kenia P, Houghton T, Beardsmore C. Does inhaling menthol affect nasal patency or cough? Pediatr Pulmonol. 2008;43:532–7.
Paul IM, Beiler JS, King TS, Clapp ER, Vallati J, Berlin CM Jr. Vapor rub, petrolatum, and no treatment for children with nocturnal cough and cold symptoms. Pediatrics. 2010;126:1092–9.
Food and Drug Administration Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Federal Register. 1983;48
Cough and cold remedies for the treatment of acute respiratory infections in young children. WHO/FCH/CAH/01.02. World Health Organization; 2001.
Cianciosi D, Forbes-Hernández TY, Afrin S, Gasparrini M, Reboredo-Rodriguez P, Manna PP, et al. Phenolic compounds in honey and their associated health benefits: a review. Molecules. 2018;23:2322.
Goldman RD. Honey for treatment of cough in children. Can Fam Physician. 2014;60(12):1107–8 (1110. PMID: 25642485; PMCID: PMC4264806).
Cohen HA, Rozen J, Kristal H, Laks Y, Berkovitch M, Uziel Y, et al. Effect of honey on nocturnal cough and sleep quality: a double-blind, randomized, placebo-controlled study. Pediatrics. 2012;130:465–71.
Oduwole O, Meremikwu MM, Oyo-Ita A, Udoh EE. Honey for acute cough in children. Cochrane Database Syst Rev. 2012(3):CD007094.
Malesker MA, Callahan-Lyon P, Ireland B, Irwin RS, CHEST Expert Cough Panel. Pharmacologic and nonpharmacologic treatment for acute cough associated with the common cold: CHEST EXPERT PANEL REPOrt. Chest. 2017;152:1021–37.
Miceli Sopo S, Greco M, Monaco S, Varrasi G, Di Lorenzo G, Simeone G, et al. Effect of multiple honey doses on non-specific acute cough in children. An open randomised study and literature review. Allergol Immunopathol (Madr). 2015;43:449–55.
Cox N, Hinkle R. Infant botulism. Am Fam Physician. 2002;65:1388–92.
Eccles R. The powerful placebo in cough studies. Pulm Pharmacol Ther. 2002;15:303–8.
Canciani M, Murgia V, Caimmi D, Anapurapu S, Licari A, Marseglia GL. Efficacy of Grintuss® pediatric syrup in treating cough in children: a randomized, multicenter, double-blind, placebo-controlled clinical trial. Ital J Pediatr. 2014;10(40):56.
Cohen HA, Hoshen M, Gur S, Bahir A, Laks Y, Blau H. Efficacy and tolerability of a polysaccharide-resin-honey based cough syrup as compared to carbocysteine syrup for children with colds: a randomized, single-blinded, multicenter study. World J Pediatr. 2017;13:27–33.
Shrivastava R, Carrois F, Pisak M, Chabrillat T, Shrivastava R. Clinical efficacy of novel filmogen, antimicrobial, cleaning, fluidizing cough treatment. J Clin Trials. 2017;7:318.
Eccles R, Mallefet P. Soothing properties of glycerol in cough syrups for acute cough due to common cold. Pharmacy (Basel). 2017;5:1.
Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, Smith JA. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomized, double-blind, placebo-controlled phase 2 study. Lancet. 2015;385(1198–20):35.
Smith J, Kitt M, Sher M, Butera P, Ford AP. A phase 2 dose-escalation study with AF-219, a P2X3 antagonist for the treatment of chronic cough. Am J Respir Crit Care Med. 2016;193:A6524.
US Nation Library of Medicine. Phase 3 Study of Gefapixant (MK-7264) in Adult Participants with Chronic Cough (MK-7264-027). 2018. https://clinicaltrials.gov/ct2/show/NCT03449134. Accessed 28 Apr 2020.
US National Library of Medicine. A Study of Gefapixant (MK-7264) in Adult Participants with Chronic Cough (MK-7264-030). 2018. https://clinicaltrials.gov/ct2/show/NCT03449147. Accessed 28 Apr 2020.
Khalid S, Murdoch R, Newlands A, Smart K, Kelsall A, Holt K, et al. Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind, randomized controlled trial. J Allergy Clin Immunol. 2014;134:56–62.
Bonvini SJ, Birrell MA, Grace MS, Maher SA, Adcock JJ, Wortley MA, et al. Transient receptor potential cation channel, subfamily V, member four and airway sensory afferent activation: role of adenosine triphosphate. J Allergy Clin Immunol. 2016;138(249–261):e12.
Birrell MA, Belvisi MG, Grace M, Sadofsky L, Faruqi S, Hele DJ, et al. TRPA1 agonists evoke coughing in guinea pig and human volunteers. Am J Respir Crit Care Med. 2009;180:1042–7.
Belvisi MG, Birrell MA, Wortley MA, Maher SA, Satia I, Badri H, et al. XEN-D0501, a novel transient receptor potential vanilloid 1antagonist, does not reduce cough in patients with refractory cough. Am J Respir Crit Care Med. 2017;196:1255–63.
US National Library of Medicine. A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants with Chronic Cough. 2019. https://clinicaltrials.gov/ct2/show/NCT03372603. Accessed 28 Apr 2020.
EU Clinical Trials Register. A Phase 2a, Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of Inhaled GRC 17536, Administered for 4 Weeks, in Patients with Refractory Chronic Cough. 2013. https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002728-17/GB. Accessed 28 Apr 2020.
Boeckxstaens GE, Rydholm H, Lei A, Adler J, Ruth M. Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther. 2010;31:1208–17.
Birring SS, Wijsenbeek MS, Agrawal S, van den Berg JWK, Stone H, et al. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomized, double-blind, proof-of-concept, phase 2 trial. Lancet Respir Med. 2017;5:806–15.
Harle ASM, Blackhall FH, Molassiotis A, Holt K, Dockry R, Russell P, et al. Neurokinin-1 receptor antagonism for the treatment of cough in lung cancer. Eur Respir J. 2016;48:PA3547.
Menlo Therapeutics Inc. Menlo Therapeutics Announces Results from a Phase 2 Clinical Trial of Serlopitant for the Treatment of Refractory Chronic Cough. 2018. https://ir.menlotherapeutics.com/index.php/press-releases. Accessed 28 Apr 2020.
Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology. 2013;38:968–75.
Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, et al. Phase 2 trial of an alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia. Schizophr Bull. 2016;42:335–43.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The publication has been supported by the Italian Society of Pediatric Allergy and Immunology (SIAIP).
Conflict of interest
Sara Manti, Mariangela Tosca, Amelia Licari, Giorgio Ciprandi, and Gian Luigi Marseglia have no conflict of interest directly relevant to the content of this article.
Availability of Data and Material
Not applicable.
Ethics Approval
Not applicable.
Consent
Not applicable.
Code availability
Not applicable.
Author contributions
All authors contributed to study conception and design. The first draft of the manuscript was written by SM and was critically revised by MAT, AL, GC, GLM. All authors read and approved the final manuscript.
Rights and permissions
About this article
Cite this article
Manti, S., Tosca, M.A., Licari, A. et al. Cough Remedies for Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 22, 617–634 (2020). https://doi.org/10.1007/s40272-020-00420-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40272-020-00420-4